Anti-inflammatory reliever (AIR) is a single inhaler treatment for asthma which can be used by people with asthma and who experience asthma symptoms twice a week or less. It removes the need to have separate preventer (brown) and reliever (blue) inhalers.
Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers.
Now is the time to make MART moves for asthma. We have been using the separate blue (reliever) and brown (preventer) inhalers for far too long. The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe. This is unsurprising, considering many patients still rely on their blue inhalers alone. However,
The asthma slide rule helps to start a conversation with your patients and colleagues around how much salbutamol is acceptable before a review is necessary
The captain of your asthma care should be your regular preventer inhaler, not the co-pilot blue inhaler.
Succinct guidance on the key elements of a good respiratory review for people with asthma
In these three case studies, clinicians explain how practices can help their patients to reduce their over reliance on short-acting beta2 agonists (SABA)